Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ContextVision Annual General Meeting

On the 6th of May 2020, ContextVision held its ordinary Shareholders' Annual General Meeting in Stockholm. · The annual financial report regarding 2019 was presented and approved by the AGM. · Disposition of financial results according to the proposal of the Board of Directors was approved. · The Managing Director and the Board of Directors were discharged from liability. · The proposed guidelines for remuneration to the Board of Directors and senior executives was approved. · Board compensation was decided according to the following: · The chairman of the board will

Verdane partners with e-health company Evondos to improve home care of elderly in Nordics

SALO/OSLO – Verdane, the specialist Northern European growth equity investor, has announced its investment in Evondos, the Finland-based Nordic leader in automated medicine dispensing services for elderly home care clients. Patient safety and the well-documented reliability of Evondos’ automated medicine dispensing service for independent living and improved medical adherence have made Evondos the partner of choice for over 200 regions and municipalities. Its growth partnership with Verdane aims to develop Evondos’ service offering and extend the company’s market leadership into Northern

Recipharm AB publishes its interim report January-March 2020

January – March 2020 · Consort Medical Plc consolidated from February 2020 · Continued solid organic growth · Net sales amounted to SEK 2,593 million (1,812), an increase of 43% · EBITDA increased by 48% and amounted to SEK 431 million (291) corresponding to an EBITDA margin of 16.6% (16.1) · EBITA increased by 56% and amounted to SEK 267 million (171) corresponding to an EBITA margin of 10.3% (9.4) · Operating profit (EBIT) amounted to SEK -29 million (111), adjusted Operating profit amounted to SEK 164 (111). · Profit after tax amounted to SEK -230 million (79)

Nordic Nanovector ASA: Increase of share capital

Oslo, Norway, 7 May 2020   Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 9,761 RSUs. The RSU’s were issued to them in May 2019 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2019 to the annual general meeting in 2020 in RSUs. In addition, board member Hilde Steineger has resolved to settle a total number of 8,818 RSUs previously issued as remuneration under the RSU-program. Each RSU gives the right to

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTarFirst quarter, 1 January –31 March 2020 · Net sales amounted to SEK 0.2 million (0.4). · The operating result totalled SEK -55.9 million (-36.7). · The result for the period amounted to SEK -56.0 million (-36.3). · Earnings per share before and after dilution amounted to SEK -2.44 (-1.59). · Cash flow from operating activities totalled SEK -59.1 million (-41.0). · At 31 March 2020, cash and cash equivalents amounted to SEK 28.3 million (26.0). Short-term investments in fixed-

SpareBank 1 SR-Bank ASA (SRBANK): Good underlying operations and strengthened solidity, but results marked by impairments and reduced financial income

SpareBank 1 SR-Bank posted a pre-tax profit of NOK 247 million at the end of the first quarter, compared with NOK 1,323 million for the same period last year. The results were marked by impairments and weak financial income. These resulted from the changed market conditions for offshore-related operations, a significantly poorer level of activity for companies in general, and weak financial markets due to the Covid-19 situation.  The return on equity after tax was NOK 3.4%, compared with 21.2% in the same quarter last year. The Common Equity Tier 1 capital ratio as at 31 March 2020 was

Gasum Group Q1 2020 - Gas plays a strong role in energy supply

Key financial indicators January 1 to March 31 2020*·The Group’s operating profit totaled €12.3 million, down 29.7% year on year (March 31, 2019: €17.5 million). · Operating profit margin in Q1 was 6.9%, up 1.4% compared with the reference year’s continuing operations (March 31, 2019: 5.5%). · Balance sheet total came to €1,133 million (March 31, 2019: €1,139 million) · The Group’s solvency remained strong in the reporting period, with the equity ratio being 44.1% (March 31, 2019: 40.7%). \* Including comparable figures for continuing operations\  Gasum Group CEO

Photocure ASA: Results for the first quarter of 2020

Oslo, Norway, 7 May 2020: Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S. market in the first quarter of 2020, contributing to Hexvix[®]/Cysview[®] revenues of NOK 54.4 million (Q1 2019: NOK 51.2 million) and an EBITDA of NOK -4.8 million (NOK -1.5 million). The company has agreed terms with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be

HKScan’s annual comparable EBIT turned positive

HKScan Corporation      Interim Report   7 May 2020 at 8:00 a.m. EETHKScan’s annual comparable EBIT turned positive  January–March 2020 · HKScan’s net sales increased by 6.8 per cent and were EUR 428.9 (401.8) million. · EBIT improved by EUR 10.8 million to EUR -3.9 (-14.7) million. · Comparable EBIT improved by EUR 6.2 million to EUR -3.9 (-10.1) million. · On an annual level (rolling 12 months), comparable EBIT turned positive and wasEUR 3.9 million. · Commercial successes and growth of sales volumes as well as operational efficiency measures were the most

Sedana Medical AB (publ), interim report Q1, 2020

Hard work to meet the intensive care needs during COVID-19Financial Summary January-March · Net sales during the quarter amounted to KSEK 33 832 (17 814) corresponding to an increase of 90% compared with the same period in 2019.  · Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to KSEK 1 204 (-2 641). This corresponds to an EBITDA margin of 3,6% (-14,8%).  · Earnings before interest and taxes (EBIT) amounted to KSEK 82 (-3 660) which corresponds to an EBIT margin of 0,2%(-20,5%).  · Earnings per share before dilution was SEK 0,07 and

Veidekke ASA: Q1 2020 results

Veidekke generated revenues of NOK 9.0 billion and a pre-tax loss of NOK 16 million in the first quarter. The construction operation order book stood at NOK 35.0 billion at quarter-end. The group’s loss per share in the quarter totalled NOK 0.70 (IFRS).“Since the COVID-19 outbreak reached Scandinavia, Veidekke has focused on limiting the spread of the virus and maintaining production. The steps we have taken have protected staff health and jobs, ensured that customer deliveries could be made as agreed and safeguarded the group’s assets,” says group CEO Jimmy Bengtsson. “The pandemic had

Otello Corporation announces first quarter results

Oslo, Norway - May 7, 2020 - Otello Corporation today reported financial results for the first quarter, which ended March 31, 2020. Please find the first quarter report (1Q20.pdf) and first quarter presentation (1Q20_presentation.pdf) attached. Audiocast: https://www.otellocorp.com/ir Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@otellocorp.com About Otello: Otello holds shares in several different businesses, including (i) AdColony which helps publishers monetize their content through advertising and advertisers reach the audiences that build value for their

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine

Sobi™  announced today that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary haemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the first therapy approved by the US Food & Drug Administration (FDA) for primary HLH and is under review by the European Medicines Agency (EMA). Primary HLH is a rare syndrome that typically presents in infancy but can also be seen in adults and is associated with high morbidity and mortality. This

Targovax ASA: First quarter 2020 results

Oslo, Norway, 7 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2020 results. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today (details below). HIGHLIGHTS FOR THE FIRST QUARTER 2020 · Entered into an option agreement with IOVaxis Therapeutics for an TG mutant RAS vaccine license and clinical development agreement in China · Presented encouraging data in the mesothelioma study

Nel ASA: First quarter 2020 financial results

(Oslo, 7 May 2020) Nel ASA (Nel) reported revenues of NOK 126.5 million in the first quarter of 2020, slightly up from NOK 122.4 million in the same quarter of 2019 and an adjusted EBITDA of negative NOK 41.7 million. The order backlog grew 46% to NOK 590 million and the company currently holds approximately NOK 1.3 billion in cash. Nel expects the Covid-19 pandemic to continue to impact financial results, but reiterates the long-term outlook.  “As we communicated in the our Covid-19 market updates 22 and 26 March, in addition to 21 April, Nel implemented strict regulations to ensure

Odfjell SE 1Q20: Improved results despite a market facing several uncertainties

Odfjell SE today reported its results for the first quarter of 2020. The report shows improved results driven by increased earnings in Odfjell Tankers as a consequence of an improved chemical tanker market. This led to positive underlying net results for Odfjell SE. Highlights for 1Q20 · EBITDA of USD 66 million, compared to USD 58 million in 4Q19 · EBITDA of USD 58 million from Odfjell Tankers compared to USD 50 million in 4Q19 · EBITDA of USD 8 million from Odfjell Terminals compared to USD 8 million in  4Q19 · Net result of USD -4 million compared to USD -10 million in

Kojamo plc: Kojamo plc’s Interim Report 1 January – 31 March 2020

Kojamo Plc Stock Exchange Release, 7 May 2020 at 8:00 a.m. EESTKojamo plc’s Interim Report 1 January – 31 March 2020 Growth in the first quarter and 1,651 Lumo apartments under construction This is a summary of the Interim Report January–March 2020, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in this Interim Report have not been audited. Summary of January–March 2020 ·

Filo Mining Reports Q1 2020 Results

Vancouver, May 6, 2020 /CNW/: Filo Mining Corp. (TSXV: FIL) (Nasdaq First North Growth Market: FIL) ("Filo Mining" or the "Company") is pleased to announce its results for the three months ended March 31, 2020.  HIGHLIGHTS: CONTINUED EXPLORATION SUCCESS AT FILO DEL SOL The 2018/2019 field season proved transformational for the Company, proving the existence of a significant porphyry copper-gold system underlying Filo del Sol’s current Mineral Resource. Following up on that success, the Company planned and executed an exploration program during the 2019/2020 field season to further

Africa Energy Reports First Quarter 2020 Results

VANCOUVER, May 6, 2020 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, announces financial and operating results for the three months ended March 31, 2020. Garrett Soden, the Company’s President and CEO, commented: “Our robust financial position--$26 million in cash, no debt and lean overhead--will allow us to weather the current economic environment brought on by the emergence of the coronavirus pandemic. We continue to focus on cost control and

Etrion to Release First Quarter 2020 Results on May 8, 2020

May 6, 2020, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, will release its first quarter 2020 results before the market opens on Friday, May 8, 2020.   Operations and Finance Update call   A conference call webcast to present the Company’s first quarter 2020 Operations and Finance update will be held on Monday, May 11, 2020, at 10:00 a.m. Eastern Standard Time (EST) / 4:00 p.m. Central European Time (CET).    Dial-in details:  Conference ID: 2070058 North America: +1-647-788-4919 / Toll Free:

Bulletin from the 2020 Annual General Meeting (AGM) of Aspire Global PLC

Today, May 6th 2020, the Annual General Meeting (AGM) of Aspire Global adopted the Consolidated Financial Statements for the 2019 fiscal year, discharged the Board of Directors and CEO from liability and re-elected the Board of Directors and the Chairman until the end of the next AGM. The AGM also resolved on four extraordinary resolutions related to the procedures for General Meetings and the authorization of the Company to acquire its own shares, including the required amendments of the Company’s articles of association. The attendants at the AGM represented 68.4% of the votes in the

Minor correction regarding calculation of key ratios

In the interim report for the first quarter 2020 that was published by Hoist Finance on 6 May 2020, there was a minor error in the calculation of the key ratios Return on Equity and Earnings per share. The correction refers to the deduction of interest expenses on AT1 capital instruments. It does not have an impact on any other key ratios nor on the Financial statements for the quarter. Return on Equity is corrected from -7 per cent to -6 per cent. Return on Equity, excluding items affecting comparability, is corrected from 5 per cent to 4 per cent. Basic and diluted Earnings per

There are no items matching the current filter
There are no more items matching the current filter
Back to top